Duloxetine

Duloxetine (CAS 116539-59-4), also referenced in development literature as LY248686, is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) active pharmaceutical ingredient used as the core therapeutic compound.

It is sourced by pharmaceutical manufacturers as a bulk API for formulation into branded and generic prescription medications. The primary application is in the manufacture of delayed-release oral capsules.

These capsules target major depressive disorder, generalized anxiety disorder, and diabetic peripheral neuropathic pain. These are product categories with sustained global generic demand for manufacturers.

Contract manufacturers and generic drug developers procure this API to produce enteric-coated pellet formulations. These pellets protect the compound through gastric transit for optimal patient absorption.

Specialty pharma companies also incorporate it into combination or modified-release formats under development. Procurement of this API is subject to ICH Q7 GMP compliance requirements for all suppliers.

Supplier qualification and documentation are central purchasing considerations for this material. It is supplied as a white to off-white crystalline powder in bulk quantities suited to commercial-scale manufacturing.

It is available in hydrochloride salt form, which is the standard pharmaceutical grade used in registered drug products. Certificates of Analysis aligned with USP and EP monograph specifications are standard.

These documents are expected by qualified buyers to ensure the highest quality standards are met. This ensures the material is suitable for use in finished-dose antidepressant and pain management drug products.